The original success of the copyright undeniably reshaped the pharmaceutical landscape, but investing in companies heavily reliant on generic versions presents a challenging picture. While early profits were significant, the cessation of patents and the rise of less expensive alternatives have weakened market share. Thus, a thorough evaluation of p